Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Novo Nordisk is chopping prices again for its popular obesity treatment Wegovy, but doctors say the expense will remain ...

New cash-paying patients can now access Wegovy/Ozempic for $199 a month. Here's what that means for Novo Nordisk stock.

The new pricing strategy aims to attract Americans willing to purchase medications directly from Novo Nordisk, bypassing insurance.

Dow Jones Top Company Headlines at 11 AM ET: Novo Nordisk Cuts Prices for Obesity Drugs | Deutsche ... The Denmark-based company slashed prices for the first two monthly doses of Wegovy and Ozempic ...